Factors Associated with the Effectiveness of Intravenous Administration of Chlorpromazine for Delirium in Patients with Terminal Cancer

Journal of Palliative Medicine
Hideaki HasuoMikihiko Fukunaga

Abstract

Delirium in patients with terminal cancer is irreversible and increases treatment resistance, which leads to a deterioration in quality of life. To investigate factors affecting the effectiveness and safety of intravenous chlorpromazine for irreversible delirium in patients with terminal cancer. Multiple regression analysis for factors affecting treatment effectiveness was carried out based on a retrospective comparison between responders and nonresponders to intravenous chlorpromazine. Ninety-seven patients with terminal cancer who were treated with intravenous chlorpromazine for irreversible delirium were included. The rate of patients with ≥50% improvement in mean Nursing Delirium Screening Scale score from pretreatment to day three of chlorpromazine treatment was 0.48 (95% confidence interval [CI]: 0.38-0.58). Factors affecting chlorpromazine treatment effectiveness were hyperactive delirium (odds ratio [OR]: 6.25, 95% CI: 1.14-34.5) and longer survival (OR: 1.096, 95% CI: 1.05-1.14). The mean chlorpromazine dose was low, at 17.9 mg/day. Adverse events were reported in 11 patients (11.3%) by day three of chlorpromazine treatment, and all were observed in patients who survived less than two weeks after chlorpromazine treatme...Continue Reading

References

Jan 1, 1993·European Journal of Clinical Pharmacology·P K YeungK K Midha
Mar 29, 2000·Archives of Internal Medicine·P G LawlorE D Bruera
Jun 21, 2002·Psychosomatics·William BreitbartChristopher Gibson
Apr 29, 2005·Journal of Pain and Symptom Management·Jean-David GaudreauMarc-André Roy
Jun 14, 2005·Schizophrenia Research·Guy Chouinard, Howard C Margolese
Sep 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-David GaudreauAnnie Tremblay
Jul 31, 2007·Journal of Pain and Symptom Management·Tatsuya MoritaYosuke Uchitomi
May 3, 2008·The Journal of Neuropsychiatry and Clinical Neurosciences·David MeagherPaula Trzepacz
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco MaltoniOriana Nanni
Jul 28, 2012·Psychiatry and Clinical Neurosciences·Yasuhiro KishiSteven Thurber
Aug 25, 2012·Journal of Palliative Medicine·Mie NagaseEtsuko Uejima
Jun 1, 2011·Palliative & Supportive Care·Soenke Boettger, William Breitbart
Feb 19, 2014·Palliative Medicine·Kristin M ZimmermanJames Rudolph
Jun 20, 2015·Palliative & Supportive Care·Fernando Espi ForcenYesne Alici
Jan 19, 2016·International Psychogeriatrics·Yasuyuki OkumuraUNKNOWN DELIRIA-J Group
Jul 28, 2016·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Aug 6, 2016·Journal of Palliative Medicine·Anniek D MasmanTeun van Gelder
May 10, 2017·Journal of Pain and Symptom Management·Jung Hye KwonDavid Hui
Sep 3, 2017·Drugs·Shirley Harvey BushPeter Gerard Lawlor

❮ Previous
Next ❯

Citations

Nov 2, 2018·Journal of Pain & Palliative Care Pharmacotherapy·Hideaki HasuoMikihiko Fukunaga
Apr 1, 2021·Revista brasileira de enfermagem·Luciana Aparecida Vieira LouroAntônio Fernandes Costa Lima

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Software Mentioned

SPSS

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here